Gene silencing. Precisely delivered.
Expanding what siRNA medicines can treat, and where they can act.
The burden of aging from chronic inflammatory disease.
Chronic, low-grade inflammation

Dysfunctional macrophages are key drivers — both causal and therapeutically actionable.
Inflammation
Inflammation that never resolves
Fibrosis
Repair that never switches off
Neurodegeneration
Maintenance turned to harm
Cardiorenal and vascular
Damage that accumulates
Most disease-driving biology remains inaccessible with conventional modalities.
Small molecules and antibodies need a binding pocket. Most disease-driving proteins don't have one.
siRNA doesn't need a pocket — it acts on the transcript, before the protein exists.
Human proteome · one square = 1%
~15%
“Druggable”
~85%
Beyond small molecules and antibodies
Each ligand opens a set of therapeutic programs.
Immune targeted
Systemic and inhaled delivery to the tissue macrophage compartment. In vivo biodistribution and silencing.
Kidney
Two paths: one ligand targeting the proximal tubule, a second reaching deeper regions of the kidney. In vivo data.
CNS
Developing small targeting ligands for TfR and other receptor-mediated pathways to enable delivery across the BBB.
Lung · non-immune
Developing small targeting ligands for selective inhaled delivery to lung epithelial cells and fibroblasts.
Other
Further tissues in discovery.
The future of drug delivery is written in sugar
CellCo is building the computational platform to decode, design, and deploy glycan-targeted therapeutics at scale.